Johnson & Johnson (NYSE:JNJ) has been assigned a $134.00 price objective by Goldman Sachs in a research note issued on Tuesday. The brokerage currently has a “sell” rating on the stock. Goldman Sachs’ price target would indicate a potential upside of 2.97% from the stock’s current price.
JNJ has been the subject of a number of other research reports. Zacks Investment Research lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Monday, April 9th. Jefferies Group set a $153.00 price target on Johnson & Johnson and gave the stock a “buy” rating in a research note on Friday. Vetr lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating and set a $124.55 price target for the company. in a research note on Monday, March 26th. Credit Suisse Group set a $154.00 price target on Johnson & Johnson and gave the stock a “hold” rating in a research note on Monday, January 22nd. Finally, Royal Bank of Canada reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, January 9th. Five investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $144.23.
JNJ stock traded down $1.62 on Tuesday, reaching $130.14. The company’s stock had a trading volume of 5,578,553 shares, compared to its average volume of 7,869,039. Johnson & Johnson has a 12-month low of $120.95 and a 12-month high of $148.32. The firm has a market capitalization of $350,440.66, a price-to-earnings ratio of 17.83, a PEG ratio of 2.08 and a beta of 0.74. The company has a quick ratio of 1.12, a current ratio of 1.41 and a debt-to-equity ratio of 0.51.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, April 17th. The company reported $2.06 EPS for the quarter, topping analysts’ consensus estimates of $2.01 by $0.05. Johnson & Johnson had a return on equity of 29.00% and a net margin of 1.70%. The company had revenue of $20.01 billion during the quarter, compared to analyst estimates of $19.50 billion. During the same quarter last year, the firm posted $1.83 earnings per share. The firm’s revenue was up 12.6% on a year-over-year basis. equities research analysts anticipate that Johnson & Johnson will post 8.11 earnings per share for the current year.
In other news, VP Paulus Stoffels sold 155,342 shares of the firm’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $129.86, for a total transaction of $20,172,712.12. Following the completion of the transaction, the vice president now directly owns 357,906 shares in the company, valued at $46,477,673.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.22% of the stock is owned by company insiders.
Several large investors have recently modified their holdings of the company. Green Square Capital LLC grew its stake in shares of Johnson & Johnson by 35.5% during the 4th quarter. Green Square Capital LLC now owns 58,280 shares of the company’s stock valued at $8,143,000 after purchasing an additional 15,273 shares during the period. Cambridge Investment Research Advisors Inc. grew its stake in shares of Johnson & Johnson by 6.4% during the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 352,547 shares of the company’s stock valued at $49,258,000 after purchasing an additional 21,076 shares during the period. Certified Advisory Corp bought a new stake in shares of Johnson & Johnson during the 4th quarter valued at about $2,751,000. Ackerman Capital Advisors LLC bought a new stake in shares of Johnson & Johnson during the 4th quarter valued at about $1,447,000. Finally, Fairfield Bush & CO. grew its stake in shares of Johnson & Johnson by 2.2% during the 4th quarter. Fairfield Bush & CO. now owns 44,871 shares of the company’s stock valued at $6,269,000 after purchasing an additional 955 shares during the period. Hedge funds and other institutional investors own 67.23% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Johnson & Johnson (JNJ) PT Set at $134.00 by Goldman Sachs” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/04/17/johnson-johnson-jnj-pt-set-at-134-00-by-goldman-sachs.html.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.